Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC

Exclusion Criteria

• •1. Prior treatment with radiation, chemotherapy, long-term or high-dose hormone therapy, or immune checkpoint inhibitors;
• •2. Previous or concurrent other malignancy;
• •3. Previous PD-L1 or PD-L1 treatment, or allergy to PD-L1;
• •4. History of primary immunodeficiency;
• •5. Active, known or suspected autoimmune diseases;
• •6. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;
• •7. Pregnant or lactating female patients;
• •8. Untreated acute or chronic active hepatitis B or hepatitis C infection. Under the condition of monitoring the virus copy number of patients receiving antiviral treatment, doctors can judge whether they are in line with the patients' individual conditions;
• •9. Have a clear history of active tuberculosis;
• •10. Participating in other clinical researchers;
• •11. Men with reproductive capacity or women who are likely to become pregnant do not take reliable contraceptive measures;
• •12. Uncontrolled concurrent diseases, including but not limited to:
• •HIV infected (HIV antibody positive); Severe infection in active stage or poorly controlled; Evidence of serious or uncontrollable systemic diseases (such as severe mental, neurological, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, liver or kidney diseases, uncontrolled hypertension \[i.e. hypertension greater than or equal to CTCAE grade 2 after drug treatment\]); Patients with active bleeding or new thrombotic disease.